Gareev, I,
Gileva, Y,
Dzidzaria, A,
Beylerli, O,
Pavlov, V,
Agaverdiev, M,
Mazorov, B,
Biganyakov, I,
Vardikyan, A,
Jin, M,
Ahmad, A (2021) of
clinical trials dedicated to oncourology have begun, using lncRNA as new biomarkers or treatments
Karasev, S.M.,
Sufianov, A.A.,
Khafizov, R.R.,
Karaseva, I.I.,
Shugushev, Z.K.,
Maximkin, D.A.,
Khafizov, T.N. (2021) -stage therapy throughout life. The article presents a
clinical case of successful endovascular treatment
-risk patients with paravalvular leak (PVL) and
clinically significant regurgitation with feasibility
.9: coronavirus infection) took part in a
clinical study at the Covid Hospital of the Bashkir State Medical
Tao, Pan,
Galiullin, D,
Chen, X.L.,
Zhang, W.H.,
Yang, K,
Liu, K,
Zhao, L.Y.,
Chen, X.Z.,
Hu, J.K. (2021) . The performance of the model was assessed with its discrimination, calibration, and
clinical usefulness. A total
Bulgakova, NA,
Vasilyeva, NA,
Imelbaeva, EA,
Shikova, YV,
Vasiliev, EA,
Salikhova, DI (2021) variety of
clinical manifestations, and a decrease in local or general factors of specific or nonspecific
Zhandabayeva, MA,
Kozhanova, KK,
Boshkayeva, AK,
Kataev, VA,
Ustenova, GO,
Gemejiyeva, NG,
Iskakbayeva, ZA (2021) clinically significant microorganisms: Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa